Sign In
Buy BMRN
$54.66
+1.34 (+2.51%)
At Close: Jun 03, 2026
BioMarin Announces Completion of Acquisition of Inozyme
08:45am, Tuesday, 01'st Jul 2025
SAN RAFAEL, Calif. , July 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (Nasdaq: I
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
10:46am, Friday, 27'th Jun 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
10:50am, Wednesday, 25'th Jun 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Data from longest and largest hemophilia gene therapy study demonstrates sustained factor VIII expression and bleed control, with 81.3% of individuals remaining off prophylaxis No new safety signals o
Here Are All 6 Stocks I've Bought Through 5 Months of 2025
03:06am, Thursday, 05'th Jun 2025
It's been a wild ride for the stock market through the first five months of 2025. As of mid-February, Wall Street's major stock indexes could do no wrong, with the benchmark S&P 500 vaulting to an all
2 top value stocks to buy for second half of 2025
06:38am, Friday, 30'th May 2025
The second half of 2025 is fast approaching, and the stock market is promising a crazy ride with some exciting news hitting the headlines.
Is the Options Market Predicting a Spike in BioMarin Pharmaceutical Stock?
12:41pm, Wednesday, 28'th May 2025
Investors need to pay close attention to BioMarin Pharmaceutical stock based on the movements in the options market lately.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
10:46am, Monday, 26'th May 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of I
BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz
10:11am, Monday, 19'th May 2025
BMRN's acquisition of INZY is set to add a late-stage enzyme replacement therapy for a rare genetic condition. The deal is likely to be closed by September.
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
07:30am, Friday, 16'th May 2025
Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected
New data in children under 5 years with achondroplasia showed treatment with VOXZOGO was associated with improvement in tibial bowing, a common cause of pain and impaired function Data from the larg
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
10:40am, Friday, 09'th May 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
10:50am, Tuesday, 06'th May 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term
10:55am, Monday, 05'th May 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
